A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Eli Lilly's CDK4/6 inhibitor Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative breast cancer, according the reveal of data from the ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

Oct 13 (Reuters) - Johnson & Johnson said the proven ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the ...

Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly drug Alimta lived about three months longer than those who received the best ...

Eli Lilly and Co.’s experimental lung cancer medicine increased survival among patients compared with those on chemotherapy alone. Shares in the Indianapolis-based drugmaker rose as much as 5.5 ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...

Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...